News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I
Regen BioPharma Provides Update On NR2F6 Small Molecule Optimization Program For Treating Cancer And Arthritis 3/24/2017
Atossa Genetics (ATOS) Opens Enrollment In Study Of Endoxifen 3/24/2017
The Science Of Sex's 'Afterglow', Psychological Science, Study Reveals 3/24/2017
Merrimack (MACK) Initiates Phase I Study Of MM-310 In Solid Tumors 3/23/2017
PROMETRIKA To Coordinate Phase I Trial For MD Anderson Cancer Center’s Institute For Applied Cancer Science 3/23/2017
FDA Provides Cornerstone Pharmaceuticals, Inc. Approval To Initiate Pivotal Study For CPI-613, Its Metabolism-Directed Anticancer Compound 3/23/2017
MediGene AG (MDGEF.PK): Announces Target And Outlines Design For Its First Clinical Trial In TCR Cancer Immunotherapy (MDG1011) 3/23/2017
Shire (SHPG) Receives FDA Fast Track Designation For Recombinant ADAMTS13 (SHP655) For Treatment Of Hereditary Thrombotic Thrombocytopenic Purpura 3/22/2017
AVEO Oncology (AVEO) Announces First Patient Dosed In Phase 1/2 Tinivo Trial Of Tivozanib And Opdivo (Nivolumab) In Advanced RCC 3/22/2017
AVROBIO Expands Rare Disease Pipeline With Gene Therapy To Treat Gaucher Disease 3/22/2017
After Patient Death a Year Ago, Cambridge's Akashi Finally Gets the OK to Resume DMD Study 3/22/2017
Intec Pharma Initiates Phase I Trial Of Accordion Pill For Cannabinoid Therapies 3/22/2017
EnGeneIC Pty Ltd Doses First Patient In U.S. Phase 1 Clinical Study Of Targeted EDV Nanocells In Recurrent Glioblastoma Multiforme 3/21/2017
Blueprint Medicines (BPMC) Announces Enrollment Of First Patient In Phase 1 Clinical Trial For BLU-667 3/21/2017
Sanofi (SNY) Announces Results Of First-Of-Its-Kind Social Experiment Revealing Real-Life Impact Of Symptoms On Allergy Sufferers In The U.S. 3/21/2017
Asterias Biotherapeutics Release: Update On Full Six-Patient Cohort Confirms Patients With Complete Paralysis Can Experience Meaningful Recovery Of Function By Six Months Following AST-OPC1 Treatment 3/21/2017
Phase II/II Clinical Trial Of Apexigen's APX005M In Combination With Pembrolizumab (Keytruda) Opens For Metastatic Melanoma Patients 3/21/2017
Minoryx Therapeutics Successfully Completes Phase 1 Clinical Trial For Lead Candidate MIN-102 3/21/2017
Madison Vaccines Expands Clinical Trial Of MVI-118 For Prostate Cancer To University of Washington 3/21/2017
Helix Release: L-DOS47 Phase I Study Results To Be Presented At The 9th International Conference Of Contemporary Oncology 3/21/2017
WntResearch Announces Positive Results From Clinical Study With Drug Candidate Foxy-5 3/21/2017
Aevi Genomic Medicine (GNMX) Craters as ADHD Drug Flunks Early-Stage Study 3/20/2017
Nordic Nanovector Announces First Patient Dosed In Phase I Study Of Betalutin In Diffuse Large B-Cell Lymphoma (DLBCL), An Aggressive Form Of NHL 3/17/2017
Sonoma Pharma (OCLS) Announces Results From Sebuderm Gel Study In Treatment Of Seborrheic Dermatitis 3/16/2017
Longeveron Achieves Milestone In Groundbreaking Stem Cell Trial For Alzheimer's Disease 3/16/2017
Kite Pharma (KITE) Highlights Publication From NCI Demonstrating Durable Complete Remissions In Patients With Relapsed/Refractory Non-Hodgkin Lymphoma Following Low Dose Conditioning Chemotherapy And Anti-CD19 CAR T-Cell Therapy 3/15/2017
Replicel Life Sciences's Phase I Clinical Trial For Hair Loss Succeeds In Meeting Primary Endpoints 3/14/2017
Lung Therapeutics Doses First Patient In Phase I Clinical Trial Of LTI-01 In Australia And New Zealand 3/14/2017
ImmunoGen (IMGN) Presents Phase I Biopsy Expansion Cohort Data At The Society Of Gynecologic Oncology Annual Meeting 3/13/2017
Celltex Therapeutics Corporation Autologous Stem Cell Case Study Published In Stem Cells And Development Demonstrates Favorable Response In Pediatric Patients 3/13/2017
Edge Therapeutics Announces First Patient Randomized In Study Of Intracisternal Administration Of EG-1962 In Adults With Aneurysmal Subarachnoid Hemorrhage 3/13/2017
Heat Biologics Meets Efficacy Endpoint In Its Phase Ib Lung Cancer Trial To Progress To Phase II 3/13/2017
Late-Breaking Abstract On LB-100, Lixte Biotechnology's Protein Phosphatase 2A Inhibitor, In Combination With A PD-1 Inhibitor In An Animal Model To Be Presented At The AACR Annual Meeting 3/10/2017
Oscar Winner Turned Pharma CEO: We’ll Prevent Genital Herpes 3/10/2017
Spotlight Innovation Commences Part 2 Of Phase I Cancer Trial 3/10/2017
Synairgen (SNG.L): Additional Positive Data In Lung Fibrosis 3/10/2017
Boehringer Ingelheim Grants Orphan Drug Designation To Boehringer Ingelheim's Investigational Anti-CD33 Monoclonal Antibody BI 836858 For Treatment Of Myelodysplastic Syndromes 3/9/2017
eFFECTOR' Lead Product Candidate, Eft508, Receives Orphan Designation From FDA For Treatment Of Diffuse Large B-Cell Lymphoma 3/9/2017
CerSci Therapeutics Awarded $225K Phase I NIH SBIR Grant For The Treatment Of Neuropathic Pain 3/8/2017
Abeona Therapeutics Receives Orphan Drug Designation In The European Union For EB-101 Gene Therapy Clinical Trial For Epidermolysis Bullosa 3/8/2017
Celyad Obtains FDA Approval To Initiate The NKR-2 CAR T Cells THINK Trial In The U.S. 3/8/2017
Cytuvax Starts Its Phase II BE RESPONDER! Study Effective Vaccination For Hepatitis B Non-Responders 3/8/2017
InDevR Release: VaxArray Flu Vaccine Potency Study Published In Vaccine 3/7/2017
Herantis Pharma's Clinical Study With Lymfactin Advances To High Dose Level 3/7/2017
Renown Pharma Announces Successful Results Of Apomorphine Sub-Lingual Spray Pharmacokinetic Study To Treat "OFF" Episodes In Parkinson's Patients 3/7/2017
FDA Lifts Clinical Hold On Seattle Genetics (SGEN)’ Cancer Drug Trial 3/6/2017
Concert Pharma (CNCE) Presents CTP-543 Phase I Results At American Academy of Dermatology Annual Meeting 3/6/2017
Deciphera Initiates A Phase 1 Clinical Trial Of DCC-3014 In Patients With Advanced Malignancies 3/6/2017
Mast Therapeutics (MSTX) Announces Clinical Study Of AIR001 For The Treatment Of Chronic Infection In Cystic Fibrosis Patients 3/6/2017
Cellceutix (CTIX) Provides Update On Developing P53 Drug Candidate Kevetrin As An Oral Anti-Cancer Agent 3/6/2017
Novartis AG (NVS) Puts Cancer Hopes on 4 Star Scientists Poached From Harvard Last Year 3/3/2017
Lexicon Pharma (LXRX) Provides Clinical Pipeline Update And Reports 2016 Fourth Quarter And Full Year Financial Results 3/3/2017
Kite Pharma (KITE)'s CAR-T Blood Cancer Candidate Succeeds in Major Study 3/2/2017
bluebird bio (BLUE) Announces Publication Of Case Study On First Patient With Severe Sickle Cell Disease Treated With Gene Therapy In The New England Journal of Medicine 3/2/2017
Mersana Presents New Data On Investigational Cancer Antibody Drug Conjugate At AACR Annual Meeting 3/2/2017
Sangamo Therapeutics (SGMO) Receives Orphan Drug Designation From The FDA For SB-913 Genome Editing Treatment For MPS II 3/1/2017
Audentes (BOLD) Announces Commencement Of LUSTRO, A Clinical Assessment And Phase I/II Run-In Study Of Patients With Crigler-Najjar Syndrome 3/1/2017
Cellectar Biosciences  (CLRB) Provides Phase I Trial Update Of CLR 131 In Multiple Myeloma: Median Progression-Free Survival Extends To 133 Days, Median Overall Survival Reaches 17.7 Months 2/27/2017
Idera Pharma (IDRA) Presents Update From Ongoing Phase I Dose Escalation Clinical Trial Of Intratumoral IMO-2125 In Combination With Ipilimumab In Metastatic Melanoma Patients Refractory To Anti-PD-1 Treatment At The 2017 ASCO-SITC Clinical Immuno-Oncology Symposium 2/27/2017
XBiotech (XBIT) Completes Dosing Of Subjects In PK Study Being Conducted In Connection With European Marketing Application 2/27/2017
Exelixis (EXEL) Announces Clinical Trial Collaboration With Roche (RHHBY) To Evaluate Cabozantinib And Atezolizumab In Locally Advanced Or Metastatic Solid Tumors 2/27/2017
Why 2017 Will be a Data-Rich and Not Revenue-Focused Year for bluebird bio (BLUE) 2/24/2017
Galapagos (GLPG.BR) Doses First Healthy Volunteer With CF Combo GLPG2222 And GLPG2451 2/24/2017
Symic Biomedical Announces Last Patient Enrolled In SHIELD Trial Of SB-030 For Interventions In Peripheral Artery Disease 2/24/2017
Trillium Therapeutics Provides Additional Details On ASCO-SITC Conference Presentation On TTI-621 2/24/2017
MabVax Therapeutics Announces FDA Authorization To Proceed With MVT-1075 In A Phase I Clinical Trial For The Treatment Of Pancreatic Cancer 2/23/2017
Zymeworks Submits ZW25 Phase 1 Clinical Study Findings Abstract For ASCO 2017 2/23/2017
Fibrocell (FCSC) Announces Dosing Of First Patient In Phase I/II Clinical Trial Of FCX-007 Gene Therapy For Treatment Of Recessive Dystrophic Epidermolysis Bullosa 2/23/2017
Acticor Biotech Has Selected Its Contract Research Organization To Manage Clinical Study Phase I 2/23/2017
CBT Pharma Presents Data Demonstrating Anti-Tumor Activity Of Its Programmed Death-1 Antibody, CBT-501, At ASCO-SITC Clinical Oncology Symposium 2/23/2017
Children’s National Health System Experts To Present Data On Novel Approach To Cell Therapy For Cancer Patients 2/23/2017
Inovio Reports New Positive Clinical Data On Vaccine Advances In The Fight Against Emerging Infectious Diseases 2/23/2017
The New England Journal of Medicine Publishes Phase Ib Results For Shire (SHPG)'s Investigational Treatment For Hereditary Angioedema, A Rare Genetic Disease 2/23/2017
Matrisys Bioscience Announces Today Publication Of Highly Promising Results Which Could Translate Into Clinically Meaningful Benefits For Eighteen Million Patients With Atopic Dermatitis 2/23/2017
ImmusanT, Inc. Announces Completion Of Phase Ib Clinical Trial Of Nexvax2 For The Treatment Of Celiac Disease 2/22/2017
Immune Design Corporation (IMDZ) Receives Orphan Drug Designation For G100 Intratumoral Product Candidate 2/22/2017
ChromaDex, Inc. Release: Study Published In PAIN Reveals Nicotinamide Riboside Is An Effective Tool In Relieving Chemotherapy-Induced Peripheral Neuropathy Induced By A Common Anticancer Agent 2/22/2017
Upon Successful Completion Of Cohort 3, Cellectar Biosciences  (CLRB) Initiates Fourth Cohort Of Its Phase I Clinical Trial Of CLR 131 In Multiple Myeloma 2/22/2017
Aethlon Medical (AEMD) Reports Results Of Cytomegalovirus, Epstein-Barr And Herpes Simplex Virus Studies 2/22/2017
Chimerix (CMRX) Announces Final Data From Advise Trial Of Brincidofovir At BMT Tandem Meetings 2/22/2017
MorphoSys AG's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study With Lanthipeptide MOR107 2/21/2017
Halloran Consulting Group Advises SEEK In Preparation For First Trial Of Vaccine To Protect Against Mosquito-Borne Diseases, Including Zika And Malaria 2/21/2017
Bellicum (BLCM) Announces Initiation Of Patient Dosing With Controllable CAR T-Cell Product Candidate 2/21/2017
Protalex (PRTX) Provides Update On U.S. And EU Studies Of PRTX-100 To Treat Immune Thrombocytopenia 2/21/2017
hVIVO Services Limited Notes The Initiation Of A Phase I Clinical Trial With AGS-V, A Mosquito-Borne Disease Vaccine Candidate 2/21/2017
3 Biotechs With the Biggest and Most Promising Pipelines 2/20/2017
Nektar Therapeutics (NKTR) Release: Clinical Data From Phase I Dose-Escalation Study Of Single-Agent NKTR-214 In Patients With Renal Cell Carcinoma Presented At The ASCO 2017 Genitourinary Cancers Symposium 2/20/2017
Exelixis (EXEL) Announces Phase 1 Trial Results For Cabozantinib In Combination With Nivolumab With Or Without Ipilimumab In Refractory Metastatic Urothelial Carcinoma And Other Genitourinary Tumors 2/20/2017
Could Marijuana Be the Next Miracle Drug For Treating Cancer? 2/20/2017
Abeona Therapeutics Provides Update From ABO-102 Phase I/II MPS IIIA Clinical Trial At The 13th Annual WORLDSymposium 2017 2/17/2017
Theravance Biopharma (TBPH) Presents Positive Clinical Data On TD-1473 At The 12th Congress Of The European Crohn's And Colitis Organization 2/17/2017
Global Blood Therapeutics (GBT) Announces Initiation Of Phase I Trial To Evaluate The Physiologic Effects Of GBT440 In Healthy Volunteers Under Hypoxemic Conditions 2/17/2017
Capricor Therapeutics, Inc. Terminates Natriuretic Peptide Program Deal With The Mayo Clinic 2/17/2017
CoCrystal To Present Clinical Data On Its Potent Pan-Genotypic NS5B Non-Nucleoside Inhibitor CC-31244 At The Asian Pacific Association For The Study Of The Liver (APASL) Annual Meeting 2/17/2017
Noble Capital Markets Initiates Research Coverage On ESSA Pharma 2/17/2017
Alexion (ALXN) Stops Work on Early-Stage Sanfilippo B Drug, Takes a $85 Million Write Off 2/16/2017
Dauntless Pharma Announces Initiation Of Phase I Clinical Trial Of Octreotide Formulation For Intranasal Delivery 2/16/2017
Zymeworks Receives Second Orphan Drug Designation For ZW25 In Gastric Cancer 2/16/2017
Assembly Biosciences (ASMB) Announces Successful Completion Of ABI-H0731 Phase Ia Trial And Upcoming Conference Presentations 2/16/2017
Berg Initiates Phase I/II Monotherapy Trial Of BPM 31510-IV In Patients With Glioblastoma Multiforme (GBM) 2/15/2017
ASLAN’ New ASLAN002 (BMS777607) Phase I Data Published In Science Translational Medicine 2/15/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters 2/14/2017
Aurinia (AUPH) Announces Results From Japanese Phase I Ethnic Bridging Study For Voclosporin 2/14/2017
Hutchison China MediTech (Chi-Med) Initiates First-In-Human Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In Australia 2/14/2017
Allergy Therapeutics Announces Novel House Dust Mite Allergy Vaccine Gains Clinical Trial Application Approval 2/14/2017
Hutchison China MediTech (Chi-Med): Initiates Phase I Of Novel FGFR Inhibitor HMPL-453 2/14/2017
Progenics (PGNX) Announces Initiation Of A Phase I Clinical Trial Of Its PSMA-Targeted Therapeutic Candidate 1095 For The Treatment Of Metastatic Prostate Cancer 2/14/2017
Hutchison China MediTech (Chi-Med) Launches Phase I Trial Of Novel FGFR Inhibitor In Australia 2/14/2017
Vaxart Announces Positive Phase I Study Of Oral Norovirus Vaccine 2/14/2017
OncoMed (OMED) Enrolls First Patient In Phase Ib Clinical Trial Of Its Anti-DLL4/VEGF Bispecific Antibody In Patients With Platinum-Resistant Ovarian Cancer 2/13/2017
TRANSGENE (ENX:TNG) And Léon Bérard Cancer Center Announce Dosing Of The First Patient In A Phase 1 Immunotherapy Clinical Trial Evaluating The Intra-Tumoral Co-Administration Of Pexa-Vec Plus Ipilimumab (Yervoy) In Solid Cancers 2/13/2017
ASLAN Announces First Patient Enrolled In Phase l Study Of Varlitinib In Japan 2/13/2017
Prevacus To Begin Phase 1 Clinical Studies Of PRV-002 For The Treatment Of Concussion 2/10/2017
Ignyta (RXDX)'s Updated Phase 1 Data On Safety, Anti-Tumor Activity And CNS Activity Of Entrectinib In Cancers With TRK, ROS1 Or ALK Fusions Published In Cancer Discovery 2/9/2017
VM BioPharma Announces Publication Of Phase I/II Clinical Data Of Novel Gene Therapy VM202 In Amyotrophic Lateral Sclerosis (ALS) 2/9/2017
MeiraGTx Provides Clinical Trial Updates For Achromatopsia And Leber's Congenital Amaurosis Ocular Gene Therapy Programs 2/8/2017
Diffusion Pharma’ TSC Phase I/II Glioblastoma Multiforme Clinical Trial Results Published In February 2017 Edition Of Journal Of Neurosurgery 2/8/2017
No Looking Back: Cellectis (CLLS) Preps for Cutting-Edge 'Off-the-Shelf' CAR-T Trial 2/7/2017
GlaxoSmithKline (GSK)'s Incoming CEO Preps for Deals, R&D Decisions on New Drugs 2/7/2017
Vyome Announces Top-Line Results From Phase 1 Study Of VB-1953 For Patients With Facial Acne Vulgaris 2/7/2017
Actinium (ATNM.OB) Announces Pipeline Expansion With Initiation Of Clinical Trial Of Actimab-M In Multiple Myeloma 2/7/2017
These 5 Biotechs Are Battling Over the $10 Billion Hemophilia Market 2/6/2017
Spyryx Biosciences Announces Successful Completion Of Phase 1 Clinical Trial For SPX-101 And Planned Phase 2 Initiation In Cystic Fibrosis During 2017 2/6/2017
Auris Med (EARS) Expands Clinical Development Pipeline With Intranasal Betahistine For The Treatment Of Meniere's Disease And Vestibular Vertigo 2/6/2017
5 Daring Biopharmas Mixing Drugs With Marijuana 2/6/2017
Addex Therapeutics (ADXN.SW)' Clinical Programs And Discovery Platform Highlighted In Review Of Allosteric Modulators For The Treatment Of Neurodegenerative Diseases 2/6/2017
NASA Sent One Identical Twin Brother To Space And Studied How It Changed Him—Here Are The First Results 2/3/2017
bluebird bio (BLUE) Announces First Patient Treated With Lentiglobintm Drug Product Under Amended Study Protocol In HGB-206 Phase I Study Of Patients With Severe Sickle Cell Disease 2/3/2017
Lysogene Receives Orphan Drug Designation From FDA For LYS-GM101 For Treatment Of GM1 Gangliosidosis 2/3/2017
Phase I Clinical Data Of ABX464, ABIVAX's First-In-Class Anti-HIV Drug, Published In Two Articles In Peer-Reviewed Journals 2/3/2017
Bionomics Limited (BNO.AX) To Receive Milestone Payment From Merck & Co. (MRK) For Initiation Of Phase I Clinical Study Of Candidate Alzheimer's Treatment 2/3/2017
Auris Med (EARS) Expands Beyond Cochlear Therapies To Include Vestibular Therapy: Intranasal Betahistine, AM-125 2/3/2017
Pfizer (PFE) Quietly Kills 3 Pipeline Programs 2/2/2017
BioMarin (BMRN) Receives Access To Priority Medicines (PRIME) Regulatory Support From EMA For BMN 270 Gene Therapy In Hemophilia A 2/2/2017
Trillium Therapeutics Doses First Patient With TTI-621 In Phase 1 Solid Tumor Trial 2/2/2017
CytomX Announces The First Patient Treated In Phase I/II PROCLAIM-072 Trial 2/2/2017
Alnylam (ALNY) Presents New Data On Fitusiran At EAHAD 2/2/2017
Catabasis (CATB) Plunges on DMD Drug Trial Failure 2/1/2017
Cambridge's Dimension Therapeutics (DMTX) Tanks to a New Low After Revealing Interim Hemophilia B Data 2/1/2017
Abeona Therapeutics Enrolls First High Dose Subject In Ongoing Phase 1/2 Gene Therapy Clinical Trial In Sanfilippo Syndrome Type A 2/1/2017
Audentes (BOLD) Announces FDA Clearance Of Investigational New Drug Application For AT342 To Treat Crigler-Najjar Syndrome 2/1/2017
6 Biopharma Companies Face Catalysts in February 1/31/2017
Cellectar Biosciences  (CLRB) Announces Two Peer Reviewed Studies Demonstrating The Capabilities Of The PDC Platform 1/31/2017
DURECT (DRRX) Announces Update On DUR-928 Development Program 1/30/2017
EyeGate Pharma Announces Positive Top-Line Data From First-In-Human Pilot Trial Of Ocular Bandage Gel In Corneal Epithelial Defects 1/30/2017
Kainos Medicines Announces Initiation Of Phase 1 Clinical Study Of KM-819 In The Treatment Of Parkinson's Disease 1/27/2017
X4 Pharma Release: Company Announces Initiation Of Clinical Study Of X4P-001 In Combination With Opdivo For Patients With Advanced Clear Cell Renal Cell Carcinoma 1/26/2017
Scientists Highlight the Hopes and Fears of Cellectis (ALCLS)' CAR-T 1/26/2017
SpinalCyte, LLC Enrolls First Patient In Landmark Phase I Human Clinical Trial 1/26/2017
Verastem (VSTM) Announces Dosing Of First Patient In Combination Trial Of Defactinib And Avelumab In Patients With Ovarian Cancer 1/26/2017
Neovia Oncology Release: Seattle Biotech Company Begins Clinical Trial For Immunotherapy Enhancing Cancer Drug 1/25/2017
Novartis AG (NVS) Shows Off 13 Potential Blockbusters in Pipeline 1/25/2017
ViraCyte Release: Company Receives Orphan Drug Designation For Viralym-C 1/24/2017
ProtoKinetix Inc. (PKTX.OB) Release: Company Announces Investigator Sponsored Human Clinical Trial Application Using AAGP Has Been Approved By Health Canada 1/24/2017
Asterias Biotherapeutics Release: Biotech Announces Additional Motor Function Improvement At 6-Months And 9-Months Following Treatment With AST-OPC1 In Patients With Complete Cervical Spinal Cord Injuries 1/24/2017
Sunesis (SNSS) Release: Biotech Announces Clinical And Regulatory Updates To SNS-062 And Vosaroxin Programs 1/23/2017
Resverlogix (RVX.TO) Release: Company Provides Groundbreaking Results In Patients With Severe Kidney Impairments 1/23/2017
Theravance Biopharma (TBPH) Release: Company Reports New Data From Ongoing TOUR Observational Patient Registry In Oral Presentation At SCCM Critical Care Congress 1/23/2017
GeoVax Labs Inc. (GOVX.OB) Release: Pharma Announces Initiation Of HIV Human Clinical Trial 1/23/2017
NantKwest Release: Landmark First-In-Human Clinical Study Launch Using A Genetically Engineered Natural Killer Cell For The Treatment Of Cancer 1/23/2017
Infinity Pharma (INFI) Release: Company Presents Preclinical Data And Phase 1 Clinical Data On IPI-549 At PI3K Keystone Symposia Conference 1/20/2017
OncoMed (OMED) Release: Company Initiates Enrollment Of Phase Ib Clinical Trial Of Brontictuzumab For The Treatment Of Metastatic Colorectal Cancer Patients 1/20/2017
ARMO BioSciences Release: Company Presents New Phase Ib Clinical Data For AM0010 In Advanced Pancreatic Cancer Patients At 2017 Gastrointestinal Cancers Symposium 1/20/2017
Abeona Therapeutics Release: Company Receives Orphan Drug Designation In The European Union For ABO-101 Gene Therapy In Sanfilippo Syndrome Type B 1/19/2017
Catabasis (CATB) Release: Company's Phase I Data On Edasalonexent (CAT-1004), A Potential Disease-Modifying Therapy Being Developed For Duchenne Muscular Dystrophy, Published In The Journal Of Clinical Pharmacology 1/19/2017
BioTime (BTX) Release: Additional Data From Company’s OpRegen Clinical Trial in Dry-AMD to be Presented At ARVO 2017 1/19/2017
Swedish Orphan Biovitrum Release: First Patients Enrolled In 24 Month Real-World Study Evaluating Effectiveness Of Elocta 1/19/2017
Lysogene Release: Biotech Receives Rare Pediatric Disease Designation From FDA For LYS-GM101 For Treatment Of GM1 Gangliosidosis 1/18/2017
WuXi AppTec Release: Novel Anti-IL-6 Antibody For Rheumatoid Arthritis From WuXi-MedImmune (AZN) Joint Venture Receives Clinical Trial Permit (CTP) From CFDA 1/18/2017
aTyr Pharma Release: FDA Grants Fast Track Designation For Company's Resolaris To Treat Limb Girdle Muscular Dystrophy 2B And Removes Partial Clinical Hold For Resolaris 1/18/2017
Daiichi Sankyo Release: Company Initiates Phase 1/2 Study Of Novel Antibody Drug Conjugate U3-1402 In Patients With HER3-Positive Metastatic Or Unresectable Breast Cancer 1/18/2017
Panacea Pharmaceuticals, Inc. Release: Company Initiates Phase I Study Of First-In-Class Cancer Vaccine Therapy Candidate In Patients With Persistent Prostate Cancer 1/17/2017
ProtoKinetix Inc. (PKTX.OB) Release: Company Announces Investigator Sponsored Clinical Trial Submitted To Health Canada For The Use Of AAGP In The Treatment Of Type 1 Diabetes 1/17/2017
Hutchison China MediTech (Chi-Med) Release: Company Presents Phase I/II Clinical Data For Selective VEGFR Inhibitor Fruquintinib At The 2017 Gastrointestinal Cancers Symposium 1/16/2017
JPM17: Why the Key to Gene Therapy Could be in an Old Bay Area Warehouse 1/16/2017
ObsEva Release: Company Announces Completion Of Phase I First-In-Women Study Of OBE022 For The Treatment Of Preterm Labor 1/13/2017
Celyad Release: Biotech Announces Registration Of The First Pancreatic Cancer Patient In Its CAR-T NKR-2THINK Trial In Belgium 1/12/2017
JPM17: Secretive Moderna Finally Unveils Pipeline, Financials 1/11/2017
Sangamo (SGMO) Release: Pharma Receives Orphan Drug Designation From The FDA For SB-318 Genome Editing Treatment For MPS I 1/11/2017
Bird Rock Bio Release: Biopharma Receives Approval To Start First In Human Clinical Trial For Namacizumab, Enters Into Agreement With GE Healthcare For Process Development And Scale-Up To Provide Clinical Phase 2 Cgmp Material, And Enters Into A Collaboration And Option Agreement With Janssen Pharmaceutical 1/11/2017
Affimed (AFMD) Release: Biopharma Provides Update On NK-Cell Immuno-Oncology Platform 1/11/2017
Corvus Pharma Announces Expansion Of Renal Cell Carcinoma Cohort In Ongoing Phase I/Ib Clinical Study Of Lead Checkpoint Inhibitor CPI-444 1/10/2017
ViraCyte Release: Pharma Granted U.S. FDA Fast Track Designation For Viralym-C 1/10/2017
Sangamo (SGMO) Release: Company Presents Latest Advances In Zinc Finger Nuclease Platform Technology At Keystone Symposium On Precision Genome Engineering 1/10/2017
Mologen (MOLGF.PK) Release: Grant To Collaboration Partner For Combination Study In HIV With Lead Product Lefitolimod 1/10/2017
Hutchison China MediTech (Chi-Med) Release: Company Initiates HMPL-523 Clinical Trials In Hematological Cancer In China 1/10/2017
BioMarin (BMRN) Release: Bay Area Biotech Solidifies Status as Top Dog in Hemophilia A Gene Therapy 1/10/2017
Sierra Oncology Successfully Transfers Sponsorship Of SRA737 Clinical Trials 1/9/2017
MabVax Therapeutics Files Investigational New Drug Application For Novel Radioimmunotherapy Agent MVT-1075 1/9/2017
Lexicon Pharma (LXRX) Begins Phase 1 Clinical Trial Of Locally-Acting SGLT1 Inhibitor, LX2761, For Potential Treatment Of Diabetes 1/9/2017
NeuroGenetic Pharmaceuticals, Inc. Completes Phase 1 Clinical Trials For NGP 555 To Treat And Prevent Alzheimer’s Disease; Shown As Safe And Well-Tolerated In Healthy Volunteers 1/9/2017
Tricida Announces Positive Topline Phase I/II Clinical Trial Results For TRC101 In 135 Subjects With Chronic Kidney Disease And Metabolic Acidosis 1/9/2017
Aridis Pharma Reports Positive Clinical Data From Phase 1/2a Study Of Human Monoclonal Antibody AR-301 For Treating Pneumonia 1/6/2017
CalciMedica Initiates Phase 1 Clinical Studies For CRAC Channel Inhibitor 1/6/2017
MacroGenics (MGNX)’ MGD006 Granted Orphan Drug Status For AML By FDA 1/6/2017
Chimerix (CMRX) Announces Preliminary Data From Ongoing Phase I Dose Escalation Study Of Intravenous Brincidofovir In Healthy Subjects 1/6/2017
Mirati Therapeutics  (MRTX) Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs 1/6/2017
RedHill Biopharma (RDHL) Announces YELIVA (ABC294640) Abstract Presentation At The 2017 Cholangiocarcinoma Foundation Annual Conference 1/6/2017
Rgenix Announces Treatment Of First Patient In Phase 1 Trial Of RGX-104, Its Lead Immuno-Oncology Therapeutic 1/6/2017
TARIS Biomedical Announces Positive Results From Ph1b Trial Of TAR-200 (Gemristm) In Patients With Muscle Invasive Bladder Cancer 1/6/2017



//-->